CD19 anticorps (AA 96-281)

N° du produit ABIN6941102

Détail du produit anti-CD19 anticorps

Antigène: CD19 (CD19 Molecule (CD19))

Épitope: AA 96-281

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD19 est non-conjugé

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), ELISA, Coating (Coat), Staining Methods (StM)

Purification: Purified by Protein A/G

Immunogène: Recombinant fragment of human CD19 protein (around aa96-281) (exact sequence is proprietary)

Clone: CD19-3117

Isotype: IgG2b kappa

Information d'application

Indications d'application:

Positive Control: Raji cells (FACS). Tonsil, Lymph Node or Spleen (IHC).

Known Application: ELISA (For coating, order antibody without BSA), ,Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur CD19

Antigène: CD19 (CD19 Molecule (CD19))

Autre désignation: CD19 (CD19 Produits)

Sujet: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Poids moléculaire: 95kDa

ID gène: 930

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway